Development of new optical source and Basic study of two-photon exciting talaporfin sodium for PDT

• Published in: Transactions of Japanese Society for Medical and Biological Engineering Vol. Annual58; no. Abstract; p. 256
• Main Authors: Yoshida, Masaki, Miyamoto, Yuichi, Toida, Masahiro
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society for Medical and Biological Engineering 2020
• ISSN: 1347-443X; 1881-4379
• DOI: 10.11239/jsmbe.Annual58.256

PDT (photodynamic therapy) is the cancer treatment. But PDT is not adapted to advanced cancers. 405nm is the peak absorption wavelength of Laserphyrin® and it does not penetrate into tissues deeply interfered with hemoglobin absorption and scattering attenuation in tissues. The next peak absorption wavelength 664nm is used for PDT now. Since the absorption rate at 405nm of Laserphyrin® is very high, the effect of two-photon excitation at 810nm can be expected. In this study, we investigate a feasibility of two-photon excitation PDT using near infrared light and compared at 810nm and 1328nm. We have developed Nd:YAG SHG pumped KTP-OPO that oscillate at both wavelengths by replacing the output coupler and adjusting phase matching angle with high peak power. In this paper, we report KTP-OPO configuration and optical properties at these wavelengths. We have accomplished 200kW peak power 20ns pulse width 50Hz repetition rate at both wavelengths.